Gaining comprehensive insight into the effect of electrocoagulation integrated in a membrane bioreactor on the detergent manufacturing plant wastewater treatment and membrane fouling.

This study evaluated the integration of electrocoagulation into a lab-scale membrane bioreactor (EC-MBR) for treating wastewater from a detergent manufacturing plant. The EC-MBR system achieved a higher chemical oxygen demand (COD) and anionic surfactant removal efficiencies of 95.1% and 99.

Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results.

Background: Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor survival rates despite current treatments. The standard of care (SOC) includes surgery, followed by radiotherapy plus concurrent and adjuvant chemotherapy with temozolomide (TMZ). This phase II trial assessed the safety and efficacy of neoadjuvant TMZ (nTMZ) before and during chemoradiotherapy in newly diagnosed GBM patients.

Anxiety-like behaviors in rats exposed to the single and combined program of running exercise and environmental enrichment.

Exercise (Ex) and environmental enrichment (EE) as the nondrug solutions have positive effects on cognitive behaviors and also increase the ability to cope with anxiety, fear, and stress. In this research, we decided to investigate the simultaneous effect of Ex and EE on anxiety-like behaviors and hippocampal neurogenesis markers in healthy rats. A total of 40 male Wistar rats were divided into four treatment groups: control, EE, Ex, and EE + Ex.

Targeting cancer-associated fibroblasts with pirfenidone: A novel approach for cancer therapy.

Cancer-associated fibroblasts (CAFs) are a heterogeneous cell population within the tumor that have recently come into the spotlight. By extracellular matrix (ECM) remodeling and robust cross-talk with cancer cells via different secretions such as cytokines, chemokines, and growth factors, CAFs contribute to cancer progression and poorer prognoses in patients. Novel candidates have been developed to inhibit CAFs; however, due to safety and efficacy issues, none have successfully passed clinical trials.